FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892091275> ?p ?o ?g. }

• W2892091275 endingPage "155" @default.
• W2892091275 startingPage "145" @default.
• W2892091275 abstract "BACKGROUNDPatients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described.METHODSWe performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan–Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology.RESULTSAfter a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival.CONCLUSIONSLow DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients. Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described. We performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan–Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology. After a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival. Low DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients." @default.
• W2892091275 created "2018-09-27" @default.
• W2892091275 creator A5023499622 @default.
• W2892091275 creator A5039838221 @default.
• W2892091275 creator A5054612339 @default.
• W2892091275 creator A5060528450 @default.
• W2892091275 creator A5065609548 @default.
• W2892091275 creator A5071536171 @default.
• W2892091275 creator A5083044879 @default.
• W2892091275 date "2019-02-01" @default.
• W2892091275 modified "2023-10-15" @default.
• W2892091275 title "Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide" @default.
• W2892091275 cites W1517688989 @default.
• W2892091275 cites W1826603175 @default.
• W2892091275 cites W1939914011 @default.
• W2892091275 cites W1984693219 @default.
• W2892091275 cites W1986624570 @default.
• W2892091275 cites W1994703155 @default.
• W2892091275 cites W2000445173 @default.
• W2892091275 cites W2001452302 @default.
• W2892091275 cites W2008423420 @default.
• W2892091275 cites W2080831548 @default.
• W2892091275 cites W2090096657 @default.
• W2892091275 cites W2100584927 @default.
• W2892091275 cites W2108221622 @default.
• W2892091275 cites W2123137799 @default.
• W2892091275 cites W2124624517 @default.
• W2892091275 cites W2125078269 @default.
• W2892091275 cites W2139036888 @default.
• W2892091275 cites W2140380756 @default.
• W2892091275 cites W2151673824 @default.
• W2892091275 cites W2153769722 @default.
• W2892091275 cites W2156293137 @default.
• W2892091275 cites W2166432084 @default.
• W2892091275 cites W2187630416 @default.
• W2892091275 cites W2188152465 @default.
• W2892091275 cites W2254626740 @default.
• W2892091275 cites W2510046349 @default.
• W2892091275 cites W2540839381 @default.
• W2892091275 cites W2561638494 @default.
• W2892091275 cites W2562287101 @default.
• W2892091275 cites W2587782289 @default.
• W2892091275 cites W2620860085 @default.
• W2892091275 cites W2765840466 @default.
• W2892091275 cites W2773049281 @default.
• W2892091275 cites W2785660664 @default.
• W2892091275 cites W2785917203 @default.
• W2892091275 doi "https://doi.org/10.1016/j.healun.2018.09.011" @default.
• W2892091275 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6556403" @default.
• W2892091275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30391191" @default.
• W2892091275 hasPublicationYear "2019" @default.
• W2892091275 type Work @default.
• W2892091275 sameAs 2892091275 @default.
• W2892091275 citedByCount "36" @default.
• W2892091275 countsByYear W28920912752019 @default.
• W2892091275 countsByYear W28920912752020 @default.
• W2892091275 countsByYear W28920912752021 @default.
• W2892091275 countsByYear W28920912752022 @default.
• W2892091275 countsByYear W28920912752023 @default.
• W2892091275 crossrefType "journal-article" @default.
• W2892091275 hasAuthorship W2892091275A5023499622 @default.
• W2892091275 hasAuthorship W2892091275A5039838221 @default.
• W2892091275 hasAuthorship W2892091275A5054612339 @default.
• W2892091275 hasAuthorship W2892091275A5060528450 @default.
• W2892091275 hasAuthorship W2892091275A5065609548 @default.
• W2892091275 hasAuthorship W2892091275A5071536171 @default.
• W2892091275 hasAuthorship W2892091275A5083044879 @default.
• W2892091275 hasBestOaLocation W28920912751 @default.
• W2892091275 hasConcept C126322002 @default.
• W2892091275 hasConcept C16020263 @default.
• W2892091275 hasConcept C164705383 @default.
• W2892091275 hasConcept C165637977 @default.
• W2892091275 hasConcept C207103383 @default.
• W2892091275 hasConcept C2777714996 @default.
• W2892091275 hasConcept C2778198053 @default.
• W2892091275 hasConcept C2779161974 @default.
• W2892091275 hasConcept C2780930700 @default.
• W2892091275 hasConcept C3018587741 @default.
• W2892091275 hasConcept C44249647 @default.
• W2892091275 hasConcept C50382708 @default.
• W2892091275 hasConcept C71924100 @default.
• W2892091275 hasConcept C78085059 @default.
• W2892091275 hasConceptScore W2892091275C126322002 @default.
• W2892091275 hasConceptScore W2892091275C16020263 @default.
• W2892091275 hasConceptScore W2892091275C164705383 @default.
• W2892091275 hasConceptScore W2892091275C165637977 @default.
• W2892091275 hasConceptScore W2892091275C207103383 @default.
• W2892091275 hasConceptScore W2892091275C2777714996 @default.
• W2892091275 hasConceptScore W2892091275C2778198053 @default.
• W2892091275 hasConceptScore W2892091275C2779161974 @default.
• W2892091275 hasConceptScore W2892091275C2780930700 @default.
• W2892091275 hasConceptScore W2892091275C3018587741 @default.
• W2892091275 hasConceptScore W2892091275C44249647 @default.
• W2892091275 hasConceptScore W2892091275C50382708 @default.
• W2892091275 hasConceptScore W2892091275C71924100 @default.
• W2892091275 hasConceptScore W2892091275C78085059 @default.
• W2892091275 hasFunder F4320306080 @default.
• W2892091275 hasFunder F4320319952 @default.

• next